Two Cases of Myelodysplastic Syndrome with Extramedullary Polyclonal Plasma Cell Proliferation and Autoantibody Production: Possible Role of Soluble Fas Antigen for Production of Excessive Self-Reactive B Cells

Internal Medicine

Volumn 37, Issue 11, 1998, Pages 973-977

  Katsuki, Kensaku ^a   Shinohara, Kenji ^a   Kameda, Naoko ^a   Yamada, Tetsuya ^a   Takeda, Koumei ^a   Kamei, Toshiaki ^a  

^a Central Hospital of Yamaguchi   (Japan)

Author keywords

Apoptosis; Gammopathy; Lymphadenopathy; Muscle abscess; Refractory anemia with excess of blast (RAEB)

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; FAS ANTIGEN; TUMOR MARKER;

AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BIOPSY; BIOSYNTHESIS; BLOOD; BONE MARROW; CASE REPORT; CELL DIVISION; FATALITY; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PLASMA CELL; REFRACTORY ANEMIA WITH EXCESS BLASTS;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD95; APOPTOSIS; AUTOANTIBODIES; B-LYMPHOCYTES; BIOPSY; BONE MARROW; CELL DIVISION; FATAL OUTCOME; FOLLOW-UP STUDIES; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; PLASMA CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032199742     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.973     Document Type: Article

References (22)

1. Hatake K, Tomizuka H, Ikeda M, et al. The presence of apoptosis in refractory anemia of myelodysplasia. in: Molecular Biology of Haematopoiesis. Abraham NG, Ed. Intercept, Andover, 1994, p. 122-133.
2. Copplestone JA, Mufti GJ, Hamblin TJ, Oscier DG. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasmacell neoplasms: a report of 20 cases unrelated to chemotherapy. Br J Haematol 63: 149-169, 1986.
3. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 63: 143-147, 1986.
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by detects in Fas antigen that mediates apoptosis. Nature 356: 314-317, 1992.
5. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976, 1994.
6. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995.
7. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946, 1995.
8. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 37: 269-390, 1985.
9. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1: 365-371, 1994.
10. Rathmell JC, Goodnow CC. Effects of the lpr mutation on elimination and inactivation of self-reactive B cells. J Immunol 153: 2831-2842, 1994.
11. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoplosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994.
12. Shinohara K, Ayame H, Yoshida T. Increased levels of soluble Fas antigen in the plasma of the patients with refractory anemia. Int J Hematol 65: 413-414, 1997 (letter).
13. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81: 346-352, 1992.
14. Gerritsen ER, Donohue J, Bauman J, et al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization. Blood 80: 217-224, 1992.
15. Osserman EH, Takatsuki K. Considerations regarding the pathogenesis of the plasmacytic dyscrasias. Series Haematologica 4: 28-49, 1965.
16. Cohen PR, Kurzrock R. Sweet'S syndrome and malignancy. Am J Med 82: 1220-1226, 1987.
17. Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoamibody production. J Immunol 138: 157-163, 1987.
18. Perkins DL, Glaser RM, Manon CA, Michaelson J, Marshak-Rothstein A. Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J Immunol 145: 549-555, 1990.
19. Sobel ES, Katagiri T, Katagiri K, Morris SC, Cohen PL, Eisenberg RA. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 173: 1441-1449, 1991.
20. Okamoto T, Okada M, Kanamaru A, Kakishita E. Analysis of immunological abnormalities associated with myelodysplastic syndrome in reference to the producibility of the lymphocytes for IL-6 and IL-10 and serum soluble Fas level. Int J Hematol 65: 628, 1997 (Abstract).
21. Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107: 89-95, 1997.
22. Yoshizaki K, Matsuda T, Nishimwo N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360-1367, 1989.